Discover oncology · 2025
To reveal the key mechanism of Citri Reticulatae Pericarpium-Reynoutria japonica Houtt in the treatment of liver cancer and its correlation with lipid metabolism: synergetic effect with network pharmacology, molecular docking and bioinformatics.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Chen, Wang Yujie, Lin Xiao, Ren Chufan, Wang Yifeng, Ma Yizhong, Zhou Jiahao, Gu Chuyu, Wang Jianyi
Аннотация
BACKGROUND: Liver cancer (LC) is a prevalent malignancy characterized by insidious onset, high recurrence rates, and significant mortality. The herbal combination "Citri Reticulatae Pericarpium-Reynoutria japonica" (CR) has traditionally been used for managing LC and related disorders, demonstrating notable therapeutic efficacy. This study aims to identify the molecular targets of CR in LC and assess its pharmacological properties and potential toxicity.
METHODS: We used GeneCards, OMIM, and TTD databases to identify targets associated with liver cancer and constructed protein-protein interaction (PPI) and herbal-target-pathway-disease interaction networks. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to explore the molecular mechanisms of CR. We also used differential expression analysis with GEO datasets (GSE76427, GSE87630, and GSE112790) to validate liver cancer-related targets and identify common core targets.
RESULTS: Survival analysis indicated that HSP90AA1 may serve as a potential biomarker for LC. Molecular docking studies showed that rhein, a compound in CR, has a strong binding affinity to the identified target proteins. This research provides robust theoretical support for the clinical application of CR in treating LC, especially in cases related to non-alcoholic fatty liver disease (NAFLD) or Metabolic Lipid Disorders (DLM).
METHODS: We used GeneCards, OMIM, and TTD databases to identify targets associated with liver cancer and constructed protein-protein interaction (PPI) and herbal-target-pathway-disease interaction networks. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to explore the molecular mechanisms of CR. We also used differential expression analysis with GEO datasets (GSE76427, GSE87630, and GSE112790) to validate liver cancer-related targets and identify common core targets.
RESULTS: Survival analysis indicated that HSP90AA1 may serve as a potential biomarker for LC. Molecular docking studies showed that rhein, a compound in CR, has a strong binding affinity to the identified target proteins. This research provides robust theoretical support for the clinical application of CR in treating LC, especially in cases related to non-alcoholic fatty liver disease (NAFLD) or Metabolic Lipid Disorders (DLM).